卵巢癌的免疫疗法

Q3 Medicine

Ejc Supplements Pub Date : 2020-08-01 DOI:10.1016/j.ejcsup.2020.02.002

Elena García-Martínez , J. Alejandro Pérez-Fidalgo

{"title":"卵巢癌的免疫疗法","authors":"Elena García-Martínez , J. Alejandro Pérez-Fidalgo","doi":"10.1016/j.ejcsup.2020.02.002","DOIUrl":null,"url":null,"abstract":"<div><p>Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 87-95"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.002","citationCount":"5","resultStr":"{\"title\":\"Immunotherapies in ovarian cancer\",\"authors\":\"Elena García-Martínez , J. Alejandro Pérez-Fidalgo\",\"doi\":\"10.1016/j.ejcsup.2020.02.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.</p></div>\",\"PeriodicalId\":11675,\"journal\":{\"name\":\"Ejc Supplements\",\"volume\":\"15 \",\"pages\":\"Pages 87-95\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.002\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejc Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359634920300033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634920300033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

摘要

卵巢癌是导致妇科癌症死亡的主要原因，迫切需要新的治疗方法。虽然肿瘤浸润淋巴细胞的存在已被证实与较好的预后有关，但免疫治疗尚未纳入卵巢癌的治疗方案。本综述简要总结了已经测试或正在研究的针对三种不同肿瘤组的策略:免疫荒漠、炎症性和免疫排除性卵巢肿瘤。最后，为了成功开发新的免疫治疗策略，需要更好地了解生物学和免疫微环境。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Immunotherapies in ovarian cancer

查看原文本刊更多论文

Immunotherapies in ovarian cancer

Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ejc Supplements 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

3.7 months

期刊介绍： EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).